Needham & Company Reiterates Hold on Garmin Ltd. (GRMN) Following Preliminary 3Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
GoPro (GPRO) Ticks Higher Amid Garmin (GRMN) Weakness
October 15, 2015 2:19 PM EDTGoPro, Inc. (Nasdaq: GPRO) is ticking higher amid a lowered outlook and cautious commentary from peer Garmin... More
Unusual 11 Mid-Day Movers 10/15: (FPRX) (AFMD) (DXCM) Higher; (IMPR) (VAC) (ACST) Lower
October 15, 2015 12:54 PM EDTFive Prime Therapeutics, Inc.(Nasdaq: FPRX) 63.0% HIGHER; Bristol-Myers Squibb Company and Five Prime Therapeutics announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Primes colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase 1 development for immunology and oncology indications. This agreement replaces the companies existing clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibbs programmed-death 1 (PD-1) immune checkpoint inhibitor, with FPA008 in six tumor... More
Pre-Open Stock Movers 10/15: (FPRX) (BOFI) (DXCM) Higher; (IMPR) (MTW) (VRX) (STX) (GRMN) (HCA) (NFLX) Lower (more...)
October 15, 2015 9:31 AM EDTFive Prime Therapeutics, Inc.(Nasdaq: FPRX) 70% HIGHER; Bristol-Myers Squibb Company (NYSE:... More
Dougherty & Co Downgrades Garmin Ltd. (GRMN) to Neutral
October 15, 2015 9:13 AM EDTDougherty & Co downgraded Garmin Ltd. (NASDAQ: GRMN) from Buy to Neutral.
For an analyst ratings summary and ratings history on Garmin Ltd. click here. For more ratings news on Garmin Ltd. click here.
Shares of Garmin Ltd. closed at $36.96 yesterday.
... MoreThe Good the Blah and the Ugly from OpCo's Emerging Tech Preview (INVN) (SYNA) (GRMN) (GLW)
October 15, 2015 8:21 AM EDTOppenheimer published its emerging technologies earnings preview titled 2 up, 1 down. Instead of covering 3 companies though it covered 12 so we sorted them based on near term outlook.
The Good:
On the positive side, theres Invensense (NASDAQ: INVN). Apple seems to be a secure customer (no design socket loss in phone, and new socket for Apple TV remote) and we expect growing share in OIS, on the other hand Samsung share is declining and we don't see any margin expansion more likely compression. No change to estimates but no expectation for... More
Garmin's (GRMN) Preliminary Q3 Results and FY Guidance Miss Estimates
October 15, 2015 7:20 AM EDTGarmin Ltd. (Nasdaq: GRMN) today announced selected preliminary financial information for its fiscal third quarter which ended September 26, 2015 and updated full year 2015 guidance.
The preliminary results of operations for the third quarter of fiscal 2015 and revised 2015 guidance represent the most current information available to management. The Companys actual results and guidance may differ materially from these preliminary results due to the completion of the companys financial closing procedures, final adjustments and other developments that may arise between the date of this press release and the time that financial results for the third... More

